# Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia

> **NCT07471516** · PHASE1,PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 2 (estimated)

## Conditions studied

- Congenital Dyserythropoietic Anemia (CDA)

## Interventions

- **DRUG:** zoledronic acid

## Key facts

- **NCT ID:** NCT07471516
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-25
- **Primary completion:** 2027-02-25
- **Final completion:** 2027-08-12
- **Target enrollment:** 2 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07471516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07471516, "Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT07471516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*